MarketLens

What is PanTracer Pro and Why Does it Matter for Cancer Diagnostics

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What is Pfizer's Braftovi and Why Does it Matter for Investors

6 months ago

What is Upstart's Cash Line and Why Does it Matter

6 months ago

What is DecisionDx-Melanoma and Why Does it Matter for Investors

5 months ago

What is Agentic Testing and Why Does it Matter for Enterprises

2 months ago

Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights

Integrated DNA Technologies (IDT) integrated its library preparation solutions with Illumina’s software ecosystem to streamline oncology research workflows. This collaboration targets faster analysis ...

DNA

Stock News•2 months ago

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

Natera enrolled the first patients in its SIGNAL-ER 101 study, a prospective, multi-center trial evaluating Signatera MRD-guided therapy de-escalation in early-stage breast cancer. The study aims to a...

NTRA

Stock News•3 months ago

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma CEO James Nathanielsz forecasts new medical breakthroughs in pancreatic cancer treatment over the next decade. The company continues its focus on developing novel therapies for recur...

PPCB

Stock News•3 months ago

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Caris Life Sciences (NASDAQ: CAI) published a study showing that Whole Exome Sequencing (WES) improves pembrolizumab eligibility accuracy. Targeted gene panels currently miscalculate tumor mutational ...

CAI